Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07392047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris

Study acronym: METROCLIN
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 6, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Acne vulgaris is a common inflammatory skin disorder. This randomized controlled trial (RCT) will compare the efficacy and safety of 2% metronidazole gel versus 1% clindamycin gel in adults with moderate acne vulgaris at Jinnah Postgraduate Medical Centre (JPMC), Karachi. Sixty eligible participants (18-35 years) will be enrolled using consecutive sampling and randomized in a 1:1 ratio using blocked randomization. Participants will apply the assigned gel as a thin layer twice daily for 12 weeks. Acne severity will be assessed using the Modified Global Acne Grading System (mGAGS) at baseline and at weeks 4, 8, and 12. The primary outcome is the proportion of participants achieving at least a 50% reduction from baseline in total mGAGS score at week 12. Local adverse effects (e.g., erythema, itching, irritation) will be recorded at each follow-up visit.
Trial Details
NCT Number NCT07392047
Lead Sponsor Jinnah Postgraduate Medical Centre
Conditions
(from sponsor)		 Acne Vulgaris
Related terms Acne Vulgaris
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov